

Waters & Sartorius join hands to enhance clone selection and process development

28 October 2021 | News

Collaboration to combine the Waters[™] BioAccord[™] LC-MS System as a bioprocess analyzer with the Sartorius Ambr® bioreactor system gives bioprocess scientists both faster and direct access to advanced quality characterization information



Waters Corporation and Sartorius have announced that they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.

Sartorius and Waters will partner to implement the BioAccord[™] LC-MS System from Waters as a new bioprocess analyzer with data connectivity to Sartorius' Ambr[®] multi-parallel bioreactor systems to deliver mass spectral information on drug substances, related analytes and cell culture media.

This combination will greatly accelerate and improve the accuracy and speed of tasks from clone selection to bioprocess optimization.

The combined offering from Sartorius and Waters aims to shorten the process from what can take over a month to two days or less, while giving more control to bioprocess scientists to obtain robust mass spectrometry data for drug substance and cell culture media samples.